Top Markets
Coin of the day
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
株式のランク #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
株価
$58.70
最終同期: 2024-01-23
時価総額
$2.98B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Mirati Therapeutics, Inc. (MRTX)

カテゴリー

Mirati Therapeutics, Inc.(MRTX)の株式分割履歴
Mirati Therapeutics, Inc.株(シンボル:MRTX)は合計で0回の株式分割を実施しました。
最新の株式分割はAug 27, 2026に行われました。
Aug 27, 2026より前に購入されたMRTX株は、現在0MRTX株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH